Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

Opinion
Video

Benjamin Maughan, MD, PharmD, examines efficacy outcomes from the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib in metastatic clear cell RCC, including how overall survival, progression free survival, and response rates compare across different baseline tumor size groups.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 9th 2025
Article
Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
September 9th 2025
Podcast
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Roman Fabbricatore
September 9th 2025
Article
A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
September 9th 2025
Podcast
The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
September 9th 2025
Article
A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
September 9th 2025
Article